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The worldwide incidence of prostatic cancer derived 
from data published by the Union Internationale 
Contre le Cancer and the International Red Cross 
Committee has been estimated to be 200,000 new 
cases each year. Cases occur predominantly in the 
USA (75 per 100,000) and in northern Europe (40 per 
100,000), whereas the incidence is low in Asia. 
Comparison of clinical series and autopsies confirms 
the high incidence of cancer in older age groups, 
although not all cases are seen clinically. Mortality 
increases more slowly than the incidence of the 
disease, indicating that diagnosis and treatment are 
increasingly effective1. 
Considering the variable biological potential of 
prostatic cancer, it becomes obvious that the diagnosis 
of malignancy does not necessarily reflect the 
individual clinical significance. The frequency of 
prostatic cancer found incidentally at post-mortem 
examinations varies between 15% and 46%; the more 
thorough the histological examination and the older 
the patient the higher the frequency2. Furthermore, 
the discrepancy between the incidence and mortality 
of prostatic cancer illustrates the variable and 
unpredictable biological potential of this disease. It 
becomes obvious that a large number of patients suffer 
from latent disease and wi l l rarely develop during 
their lifetime any clinical manifestation requiring 
therapeutic intervention. These patients might be 
exposed, if their tumours were detected, to the risks 
of unnecessary treatment. 
In a population-based regionally well-defined study 
of 223 patients (mean age 72 years) with early-stage 
(T0-2, Nx, M0) initially untreated prostatic cancer, the 
10-year, disease-specific survival rate was 86.8%, and 
this was equally high (87.9%) in a subgroup of 
58 patients who met current indications for radical 
prostatectomy3. 
However, approximately one third to one quarter 
of the men in whom clinical prostatic cancer develops 
wil l die of the disease. These considerations underline 
the need to recognize those patients who require 
intervention. In carefully selected series, 40% of men 
who undergo radical prostatectomy have extra-
prostatic disease4. For low-stage disease, curative 
treatment modalities are available; survival rates after 
radical prostatectomy equal those of the normal male 
age-matched population. Comparing the 10-year 
survival rates of patients with stage p T l and 
pT2pN0M0 after radical prostatectomy of 95% and 
70%, respectively, to the corresponding rate of 60% 
in cases with tumours extending through the capsule, 
a stage-related prognostic difference is evident5. 
McNeal has proposed that biologically aggressive 
behaviour in adenocarcinoma of the prostate may be 
a direct function of cancer volume. In a study of over 
200 radical prostatectomy specimens, the morpho­
logical variables such as capsule penetration, seminal 
vesicle invasion and positive surgical margins strongly 
correlated with cancer volume. Metastatic potential 
was most strongly predicted by a combination of 
tumour volume plus the percentage of high-grade 
tumour (quantified by Gleason grading); cancers with 
more than 3 2 cm 3 of a grade 4 and/or 5 component 
showed a 100-fold increase in the proportion of cases 
with nodal spread6. Furthermore, carcinomasNof the 
prostate with a volume < 1 cm 3 were usually well 
differentiated and subsequently dedifferentiate into 
moderately and poorly differentiated carcinomas as 
they increase in size. With increasing size and 
dedifferentiation they were increasingly likely to 
mestastasize7. 
These findings might suggest that detection of 
prostatic cancer by screening at an early and—by 
definition—more treatable stage, could result in a 
decrease of mortality by at least preserving the option 
for curative therapy. However, early detection would 
reveal a proportion of cancers not destined to impact 
on prostatic cancer mortality rates. Detection of such 
clinically 'unimportant' cancers would lead to 
therapeutic overkill, and one form of bias—whereby 
the apparent benefit from screening was reflected in 
a diminished mortality rate in the screened popula­
tion—would be a consequence of the diagnosis (and 
treatment) of clinically irrelevant cancers8. 
For screening in general reasonably high specificity 
of a test is required i f an unmanageable number of 
false-positive cases is to be avoided. However, the 
properties of the screening test, no matter how good 
they are, reveal nothing about the impact that screen­
ing might have on the consequences of a cancer9. 
Another important prerequisite for a screening 
programme is a reliable method for assessing the 
progression capability (growth rate and metastatic 
potential) of a detected tumour. The occurrence of 
rapidly progressing cancers, which escape detection 
at the initial examination but which progress beyond 
potential curability in the interval between screenings, 
would reflect adversely on a screening programme8. 
In the presence of limited financial and medical 
resources a further important component of screening 
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evaluation is cost. Screening costs include the cost of 
the test, the cost of side effects of the test, and the 
cost of biopsy and treatment; while screening benefit 
can be measured in terms of lives saved, life years 
saved, or quality-adjusted life years9. In the United 
States a mass screening programme using transrectal 
ultrasound (TRUS), and the anticipated treatment of 
men aged 50-70 years for carcinoma of the prostate 
arising therefrom, would change spending allocation 
from 0.06% of the total US health care budget to more 
than 5%, and if prostate-specific antigen (PSA) 
determination were included even to 6%. Adoption 
of such a programme would obviously require 
significant cutbacks in other services or a significant 
increase in federal or private health care spending10. 
Modalities for diagnosis of prostatic cancer 
Since there is no characteristic symptom that occurs 
at an early stage of prostatic cancer, the diagnosis is 
usually established incidentally by discovering a 
nodule on rectal examination as part of a routine 
physical examination, or by histology after operation 
for ostensibly benign disease, or at autopsy. Only a 
decade ago transurethral resection was still the most 
common way of establishing the diagnosis of prostatic 
cancer (56.6% in 1983), followed by digital rectal 
examination (DRE) (45%) n . In recent years trans­
rectal ultrasound (TRUS)" and the determination of 
serum levels of PSA have enlarged the diagnostic 
armamentarium; their impact for screening has been 
evaluated both as single measures and in combination. 
Digital rectal examination (DRE) 
Palpation of the prostate is hampered by its 
subjectivity, since 32% of carcinomas wi l l be missed 
even by experienced examiners12. A review of the 
results of routine urological screening of 2005 men 
aged 40-70 years for adenocarcinoma of the prostate 
demonstrated that DRE is an insensitive screening 
device with poor predictive value 1 3. 
Friedman et al14 conducted a case-control study 
comparing, in 139 men with metastatic carcinoma of 
the prostate and an equal number of matched men 
free of this condition, the history of rectal examina­
tions before prostatic cancer was diagnosed. In the 
10 years before initial diagnosis the average number 
of examinations for routine screening (2.45 v. 2.52) 
or to evaluate intestinal or rectal symptoms (0.44 in 
both) were similar in cases and controls. After 
adjustment for racial differences, the relative risk of 
metastatic prostatic cancer for men with one or more 
screening rectal examinations compared with men 
with none was 0.9, with a 95% confidence interval 
of 0.5-1.7. The authors concluded that screening by 
routine digital examination appears to have little i f 
any effect in preventing metastatic prostatic cancer. 
Thus, i f there is a small benefit, it w i l l be difficult to 
demonstrate by a conventional epidemiological study. 
Phillips & Thompson15* reviewing 96 patients who 
died from prostatic cancer, found that, as a minimum, 
any attempt at early detection using annual DRE 
within this population of men could not have 
prevented 25% of the deaths from prostatic cancer, 
since these patients exhibited a palpably normal gland 
at the time of diagnosis. On the other hand, several 
studies have revealed that approximately 50% of 
cancers detected through DRE screening had already 
spread beyond the prostate1 6. 
However, even recognizing the limitations of this 
clinical test, it remains the cheapest and simplest 
evaluation of the prostate gland and no test has yet 
been proved to be better. At this time, DRE remains 
the principal method for early detection and staging 
of prostatic carcinoma1 5. 
The key to demonstrating an overall benefit from 
prostatic screening is a diminished disease-specific 
mortality rate. To date, this has not been shown. 
Lower mortality rates from prostatic cancer can be 
demonstrated only through a randomized study 
comparing screened and unscreened populations 1 6. 
In 166 patients with a palpable abnormality within 
the prostate suspicious for carcinoma, the echotexture 
was correlated with the histopathological report 1 5 . 
In 47 cases prostatic cancer was diagnosed whereas 
in 119 patients a benign condition only was proved. 
The ultrasound finding with the highest predictive 
value for carcinoma was that of a hypoechoic lesion. 
Nevertheless, it is noteworthy that 49% of palpable 
prostatic cancers had TRUS findings other than those 
of hypoechoic lesions. Indeed, fully 43% of all 
tumours were isoechoic. However, 36% of the benign 
lesions also appeared hypoechoic and 55% isoechoic. 
Thus, it is unclear how TRUS wi l l interface with DRE 
because of the multiple echo patterns that prostatic 
diseases, regardless of diagnosis, can exhibit 1 5 . 
Transrectal ultrasound (TRUS) 
Advances in technology, especially the improved 
resolution since the introduction of high-frequency 
transducers, have allowed for a more precise 
visualization of the infrastructure of the prostate. 
However, the quality of the equipment employed as 
well as the investigator's expertise wi l l influence the 
sonographic diagnosis. Lee et al.11 found that the 
overall detection rate for prostatic cancer with TRUS 
was twice as high as with DRE (2.6 versus 1.3%). The 
sensitivity of TRUS was also twice as high as DRE, 
which prompted the authors to advocate broader 
implementation and evaluation of TRUS as a tool for 
early detection. In a study of 2400 randomly selected 
men (age 55-70 years) for early detection of prostate 
cancer, Norming et α / . 1 8 found that TRUS added 
significantly to the detection rate of 35%. I f radical 
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Table 1. Statistical characteristics of PSA, DRE and TRUS as single modalities in the detection of prostatic cancer 
Sensitivity (%) Specificity (%) PPV (%) 
PSA (ng/ml) 
A l l h o f f et a l 1 9 
A l l h o f f et al™ 
Babaian et al.21 
Brawer 2 2 
Catalona et al.23 
Delaere et al.24 
Powel l et al.25 
>2.7 
90 
93 
80 
>4 
88 
81 
65 ' 
79 
>10 
70 
64 
57 
89 
>2.7 
50 
39 
58 
>4 
50 
82 
69 
59 
>10 
90 
76 
88 
90 
>2.7 
70 
45 
> 4 
49 
50 
40 
>10 
90 
59 
47 
TRUS 
A l l h o f f «> /« / . 2 0 
Babaian Λ / . 2 1 
Carter al.2(i 
Catalona et al.2!i 
Palken et al.27 
77 
84 
52 
92 
61 
62 
82 
68 
27 
36 
52 
54 
28 
27 
DRE 
Al lho f f et al20 
Babaian et al21 
Catalona et al.23 
Palken et al.21 
80 
89 
86 
74 
70 
84 
44 
53 
59 
33 
38 
Predicted PSA (TRUS gland volume χ 0.2 ng/ml/g) 
Lee et ai.M 2 3 — - 8 8 3 7 — » - 7 2 
PPV = positive predictive value; PSA = prostate-specific antigen; TRUS = transrectal ultrasound; DRE = digital rectal examination 
surgery is restricted to stages T l and T2a, the 
combined use of DRE and TRUS detected twice as 
many cases fit for this treatment as DRE alone. 
On the other hand, due to its low specificity, 
ranging between 27% and 82%, TRUS cannot be 
considered a first-line screening test for prostatic 
cancer (Table 1). Only 60% of tumours are hypo­
echoic, and hyper- or isoechoic malignancies are 
difficult or impossible to detect, which also applies 
to the 25% of cancers arising in the poorly echogenic 
transitional zone. In addition, tumours < 0.5 mm in 
diameter escape the spatial resolution of TRUS2 9. 
A prostatic cancer screening study of 315 asympto­
matic men by Palken et al.50 comparing DRE and 
TRUS identified 23 cancers, a detection rate of 7.3%. 
Seventeen (5.4%) were diagnosed by DRE. Contrary 
to the experience of others, this was a higher rate than 
that achieved by TRUS (14 cases or 4.4%). DRE and 
TRUS identified the same number of patients with 
small ( < 1.5 cm 3) cancers, contrary to other reports 
that found TRUS to be superior. The authors consider 
DRE an effective screening examination, equivalent 
to TRUS and preferable because of lower cost. 
Coffield et aOx correlated the TRUS detection of 
prostatic adenocarcinoma with 63 histological whole-
mount step-sectioned prostatic specimens harvested 
from 148 consecutive autopsies. No patient had known 
or palpably-suspected prostatic adenocarcinoma on 
pre-mortem DRE. Prostate specific antigen (PSA) was 
assayed in each case from pre-mortem serum samples. 
Of 19 cancers, 32% were detected by TRUS and all 
were hypoechoic. Of the 13 non-detected cancers, 7 
were isoechoic, 3 were mixed hypoisoechoic, 2 were 
hypoechoic and one was mixed hyperisoechoic. PSA 
> 4 ng/ml would have aided in cancer detection by 
suggesting the need for biopsy or further biopsy in 
5 cancers with significant volume which were missed 
by TRUS. The sensitivity (32%) and specificity (64%) 
of TRUS appeared to be too low for use in clinical 
screening for prostatic adenocarcinoma. In this series 
PSA and TRUS together appeared to be more effective 
than sonography alone in the detection of prostatic 
adenocarcinoma. 
TRUS seems more appropriate as an adjunct to 
biopsy. Rifkin et al.52 compared the accuracy of 
digitally guided biopsy versus ultrasound-guided 
biopsy of the prostate in 112 consecutive men with 
palpable prostatic lesions. In 44 patients (39.3%) with 
negative results on conventional biopsy, the results 
of ultrasound-guided biopsy revealed cancer. 
Prostate-specific antigen (PSA) 
The detection of prostatic cancer by DRE and TRUS 
is not infallible, since malignancies may be neither 
palpable nor visible on ultrasound. Thus, the intro­
duction of PSA by Wang and associates in 1979 opened 
a new era in the diagnosis of prostatic disease, enabling 
intrinsic glandular alterations to be monitored 3 3. 
PSA is a 34 kd-240-amino acid glycoprotein, 
synthesized exclusively by the epithelial cells of the 
ducts and acini of the mature prostate and secreted 
into the seminal fluid. Its function is assumed to be the 
digestion of the seminal vesical-specific antigen and 
liquefaction of the semen coagulum34. Entry into the 
circulation therefore demonstrates only inappropriate 
secretion, characterizing PSA as a 'reactive' marker, 
a fact which should always be considered when 
results are interpreted. A variety of causes is known 
for PSA-elevation in benign conditions (Table 2). Most 
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Table 2. Non-cancerous causes of PSA elevation55'*9 
Benign prostatic hyperplasia 
Infarct ion 
Prostatitis 
Mechanical alteration: 
Instrumentation (biopsy, TURP) 
Massage 
Palpation (not immediately) 
Urinary retention 
Interferences (drugs, metabolic disorders) 
Alterat ion o f PSA metabolism 
important is its possible role as an indicator of 
prostatic malignancy, with a sensitivity ranging 
between 65% and 88% when the titres exceed the 
normal ranges of the employed test kits. However, 
in cases of moderate PSA elevation, the lack of 
specificity with respect to malignant disease and the 
poor positive predictive value of the test, as well as 
the fact that a PSA within the normal range does not 
exclude prostatic cancer, limits the use of this serum 
marker as single measure for early detection (Table 1). 
This is due to the critical overlap with non-cancerous 
causes as well as to multiple biological factors in cases 
of malignancy which might impact on the markers 
level (Table 3). 
In our own series19 PSA levels were within the 
normal range in approximately 10% despite the 
presence of prostatic cancer. Looking at the various 
PSA levels within the intermediate range (4.Ο­
ΙΟ ng/ml, monoclonal assay) with respect to the 
diagnosis of the underlying disease, a shifting of the 
statistical characteristics could be observed. With 
increasing values an increasing specificity indicating 
malignancy was associated with a loss in sensitivity 
and vice versa (Table 1). This was mainly caused by 
approximately 25% of patients with malignant disease 
exhibiting PSA titres within the intermediate range19. 
WhilstNnot overlooking PSA's indicative potential, 
serial determinations are therefore mandatory not 
only to confirm the previous value but also to obtain 
the individual's PSA kinetics longitudinally. Carter et 
al.45 found the rate of change in PSA levels to be 
significantly greater in subjects with prostatic cancer 
compared with control subjects and subjects with 
benign prostatic hyperplasia (BPH). Also, the rate of 
change in PSA levels distinguished subjects with 
prostatic cancer from those with BPH and controls 
with a specificity of 90% and 100%, respectively45. 
To distinguish further between benign and 
malignant prostatic conditions in cases of moderate 
PSA elevations, volume-adjusted upper limits of 
Table 3. Biological factors impacting on PSA titre in malignant 
disease*0-" 
Intra- individual variat ion 
Variat ion i n the relative amount o f epi thel ium 
Unpredictable BPH component 
Variable PSA synthesis due to tumour heterogeneity 
Genetic instability dur ing tumour g r o w t h 
normal PSA can be determined for the different levels 
of specificity desired. Kane et al.46 found a direct 
relationship between serum PSA levels and estimated 
prostatic volume for both the currently available 
monoclonal and polyclonal PSA assays. Benson et 
al41 used TRUS-determined prostatic volumes in a 
well-defined population of 535 men to form a serum 
PSA/prostatic volume ratio called prostate-specific 
antigen density (PSAD) (monoclonal assay). Dis­
criminant analysis according to negative or positive 
outcome allowed for the construction of nomograms, 
which resulted in a PSAD-defined cancer risk ranging 
from 3% to 100%, thus allowing for a more indi­
vidualized interpretation of PSA. A similar approach 
by Lee and coworkers 2 8 employing a predicted PSA 
value (TRUS gland volume χ 0.2 ng/ml/g = polyclonal 
PSA), resulted in an improvement of the TRUS-
positive predictive value (PPV) from 52% to 86% 
when serum PSA exceeded the predicted value 
(Table 1). 
A study performed by Babaian & Camps 4 8 
confirmed the proportional relationship between PSA 
level and the risk for prostatic cancer, indicated in 
Table 1, showing the increasing specificity of the 
marker at an extended range. They advocated that, 
regardless of other findings, all patients with an initial 
PSA value > 10 ng/ml (monoclonal assay) require 
biopsy because of the high likelihood of cancer 
(83.3%). This is supported by the results of Catalona 
et al.25 who found a 67% rate of prostatic cancer in 
such patients. 
Combined approach 
The limited capacity of DRE, TRUS and PSA reliably 
to detect prostatic cancer prompted numerous 
efforts to develop a multi-modality approach which 
might help to promote cancer control by early 
diagnosis. 
Lee and coworkers 1 7, comparing the clinical 
usefulness of TRUS and DRE in a screening programme 
examining 784 men over age 60 years, achieved a 
positive predictive value (PPV) that was higher (50%) 
than for TRUS alone (31 %) or DRE alone (34 % ) , when 
the results from both DRE and TRUS were positive 
(Table 4). 
Catalona et al?*, presenting a study based on PSA-
determination as a first-line test in 1653 healthy men 
aged over 50 years, found that of the two-test 
combinations, PSA measurement plus DRE gave the 
lowest error rate. In their series 22% of the men wi th 
PSA levels of 4-9.9μ%1\ and 67% with PSA levels 
^10 /ig/l had prostatic cancer on biopsy. If DRE alone 
had been used to screen the men who had biopsies, 
32% would have been missed. If TRUS had been used 
to screen these men, 43% would have been missed. 
The authors concluded that the combination of DRE 
and PSA, wi th TRUS performed in patients wi th 
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Table 4. PPVs (%) employing the various modalities as single measures or in combination 
DRE TRUS PSA 
DRE + 
TRUS 
DRE + 
PSA 
DRE + 
PSA + 
TRUS 
Al lho f f et al.20 59 52 49 62 74 78 
Babaian et al.49 6 5 — 15 27 62 
Cooner et al.50 43 — 48 — 62 — 
Lee et aV 34 31 — 50 — — 
Perrin et al.51 51 6 — 58 — 
PPV = positive predictive value; DRE = digi tal rectal examination; TRUS = transrectal ultrasound; 
PSA = prostate-specific antigen 
abnormal findings, provided a better method of 
detecting prostatic cancer than DRE alone. 
Superiority of the combination 'DRE and 
PSA>4 ng/ml' was also demonstrated recently by our 
own group in a prospective study of 1230 patients 
over 40 years of age, in which DRE, TRUS and PSA 
were correlated in all possible combinations under 
various conditions (requiring at least one of the 
parameters or all to be positive for reliable diagnosis). 
As a first-line approach, DRE plus PSA > 4 ng/ml enabled 
the detection of prostatic cancer with a specificity of 
86.5% and PPV of 74%. TRUS did not contribute 
significantly to the final diagnosis20 (Table 4). 
Finally, the findings of a similar project by the 
American Cancer Society exposed the influence of the 
diagnostic triad on the prostatic cancer detection rate. 
Amongst the men found to have cancer (n = 88/2425), 
TRUS was abnormal in 80.6% and the PSA level and 
DRE were abnormal in 67% and 50%, respectively. 
The influence of PSA levels on cancer detection 
increased as the serum level increased above 4 ng/ml. 
The PPVs of both DRE and TRUS were influenced 
significantly by the presence of an elevated PSA level 
(P = 0.044 and P< 0.001, respectively). The results of 
this ongoing multi-centre study support the statement 
that the detection rate of organ-confined disease 
can be improved substantially by early detection 
programmes49. Nevertheless, the optimal diagnostic 
algorithm still remains to be defined and its validity 
prospectively confirmed. 
Perspectives 
Despite these promising results, no study has proved 
that routine screening reduces mortality from 
prostatic cancer. Therefore the European Programme 
against Cancer is supporting a study of the feasibility 
of screening for prostatic diseases. Two slightly 
different studies, both randomized and prospective, 
were launched in Rotterdam (October 1991, Director 
F Schröder) and Antwerp (November 1990, Director 
L Denis) comparing the overall mortality in the 
screened populations with that in the control groups. 
It wi l l take about eight years before valid data with 
respect to mortality are available52. Hopefully these 
studies wi l l confirm that screening wi l l detect greater 
numbers of potentially morbid or lethal cancers, so 
that treatment wi l l become possibly in more patients 
for whom it is necessary. 
However, our research should focus on the 
development of prognostic features that accurately 
predict the potential of an individual tumour and thus 
also enable selection of those patients in whom 
unnecessary treatment can be avoided. 
Meanwhile, in equivocal selected cases, our current 
knowledge of the characteristics and potential of the 
various diagnostic techniques may be an advantage 
in the differential diagnosis of prostatic cancer. 
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